309 related articles for article (PubMed ID: 33657875)
1. Providers' perspectives on the clinical utility of pharmacogenomic testing in pediatric patients.
Liko I; Lee YM; Stutzman DL; Blackmer AB; Deininger KM; Reynolds AM; Aquilante CL
Pharmacogenomics; 2021 Apr; 22(5):263-274. PubMed ID: 33657875
[No Abstract] [Full Text] [Related]
2. Stakeholder perspectives of the clinical utility of pharmacogenomic testing in solid organ transplantation.
Deininger KM; Tran JN; Tsunoda SM; Young GK; Lee YM; Anderson HD; Page Ii RL; Hirsch JD; Aquilante CL
Pharmacogenomics; 2019 Dec; 20(18):1291-1302. PubMed ID: 31755847
[No Abstract] [Full Text] [Related]
3. Attitudes about pharmacogenomic testing vary by healthcare specialty.
Preys CL; Blout Zawatsky CL; Massmann A; Heukelom JV; Green RC; Hajek C; Hickingbotham MR; Zoltick ES; Schultz A; Christensen KD
Pharmacogenomics; 2023 Jul; 24(10):539-549. PubMed ID: 37458095
[No Abstract] [Full Text] [Related]
4. Perspectives of Pediatric Providers Regarding Clinical Use of Pharmacogenetics.
Avello K; Bell M; Stein Q; Bares V; Landsverk M; Salyakina D; McCafferty-Fernandez J; Kingsmore S; Bedrick A; Bhojwani D; Hoyme HE
S D Med; 2021 Jul; 74(7):294-301. PubMed ID: 34449988
[TBL] [Abstract][Full Text] [Related]
5. PGx in psychiatry: Patients' knowledge, interest, and uncertainty management preferences in the context of pharmacogenomic testing.
Kastrinos A; Campbell-Salome G; Shelton S; Peterson EB; Bylund CL
Patient Educ Couns; 2021 Apr; 104(4):732-738. PubMed ID: 33414028
[TBL] [Abstract][Full Text] [Related]
6. Assessment and clinical utility of pharmacogenomics by healthcare practitioners in North Carolina.
Raccor BS; Thompson DK; Thomas C; Hill AK; Shields K; Alcala-Williams I; Cartrette T; Fasinu P; Al-Achi A
Pharmacogenomics; 2021 Jan; 22(1):13-25. PubMed ID: 33356552
[No Abstract] [Full Text] [Related]
7. Providers' Use of Pharmacogenetic Testing to Inform Antidepressant Prescribing: Results of Qualitative Interviews.
Vest BM; Wray LO; Thase ME; Brady LA; Chapman SR; Oslin DW
Psychiatr Serv; 2023 Dec; 74(12):1270-1276. PubMed ID: 37528698
[TBL] [Abstract][Full Text] [Related]
8. Non-interventional cardiologists' perspectives on the role of pharmacogenomic testing in cardiovascular medicine.
Deininger KM; Page RL; Lee YM; Kauffman YS; Johnson SG; Oreschak K; Aquilante CL
Per Med; 2019 Mar; 16(2):123-132. PubMed ID: 30543145
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic testing in oncology: a health system's approach to identify oncology provider perspectives.
Bhatt M; Peshkin BN; Kazi S; Schwartz MD; Ashai N; Swain SM; Smith DM
Pharmacogenomics; 2023 Nov; 24(16):859-870. PubMed ID: 37942634
[No Abstract] [Full Text] [Related]
10. Primary care physician experiences with integrated pharmacogenomic testing in a community health system.
Lemke AA; Hutten Selkirk CG; Glaser NS; Sereika AW; Wake DT; Hulick PJ; Dunnenberger HM
Per Med; 2017 Sep; 14(5):389-400. PubMed ID: 29754567
[TBL] [Abstract][Full Text] [Related]
11. Assessment of primary care practitioners' attitudes and interest in pharmacogenomic testing.
Smith DM; Namvar T; Brown RP; Springfield TB; Peshkin BN; Walsh RJ; Welsh JC; Levin B; Brandt N; Swain SM
Pharmacogenomics; 2020 Oct; 21(15):1085-1094. PubMed ID: 32969759
[No Abstract] [Full Text] [Related]
12. Pharmacogenomic Testing for Major Depression: A Qualitative Study of the Perceptions of People with Lived Experience and Professional Stakeholders.
Slomp C; Morris E; Edwards L; Hoens AM; Landry G; Riches L; Ridgway L; Bryan S; Austin J
Can J Psychiatry; 2023 Jun; 68(6):436-452. PubMed ID: 36437757
[TBL] [Abstract][Full Text] [Related]
13. Comfort with Pharmacogenetic Testing Amongst Pediatric Oncology Providers and Their Patients.
Mowbray C; Turner J; Gai J; Jacobs S
J Pediatr Hematol Oncol Nurs; 2022; 39(3):168-177. PubMed ID: 35467433
[No Abstract] [Full Text] [Related]
14. Patients' Perspectives on Psychiatric Pharmacogenetic Testing.
Liko I; Lai E; Griffin RJ; Aquilante CL; Lee YM
Pharmacopsychiatry; 2020 Nov; 53(6):256-261. PubMed ID: 32583391
[TBL] [Abstract][Full Text] [Related]
15. Primary care and mental health providers' perceptions of implementation of pharmacogenetics testing for depression prescribing.
Vest BM; Wray LO; Brady LA; Thase ME; Beehler GP; Chapman SR; Hull LE; Oslin DW
BMC Psychiatry; 2020 Oct; 20(1):518. PubMed ID: 33115428
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.
Cohn I; Manshaei R; Liston E; Okello JBA; Khan R; Curtis MR; Krupski AJ; Jobling RK; Kalbfleisch K; Paton TA; Reuter MS; Hayeems RZ; Verstegen RHJ; Goldman A; Kim RH; Ito S
JAMA Netw Open; 2021 May; 4(5):e2110446. PubMed ID: 34037732
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on the Clinical Use of Pharmacogenetic Testing in Late-Life Mental Healthcare: A Survey of the American Association of Geriatric Psychiatry Membership.
Bousman CA; Oomen A; Jessel CD; Tampi RR; Forester BP; Eyre HA; Lavretsky H; Müller DJ
Am J Geriatr Psychiatry; 2022 May; 30(5):560-571. PubMed ID: 34740522
[TBL] [Abstract][Full Text] [Related]
18. Results of a nationwide survey of Japanese pharmacists regarding the application of pharmacogenomic testing in precision medicine.
Tsuji D; Saito Y; Mushiroda T; Miura M; Hira D; Terada T
J Clin Pharm Ther; 2021 Jun; 46(3):649-657. PubMed ID: 33555613
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
Verbelen M; Weale ME; Lewis CM
Pharmacogenomics J; 2017 Oct; 17(5):395-402. PubMed ID: 28607506
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic testing in primary care practice: opinions of physicians, pharmacists and patients.
Frigon MP; Blackburn MÈ; Dubois-Bouchard C; Gagnon AL; Tardif S; Tremblay K
Pharmacogenomics; 2019 Jun; 20(8):589-598. PubMed ID: 31190623
[No Abstract] [Full Text] [Related]
[Next] [New Search]
